Building the next generation of regenerative therapies
Komava Biotherapeutics is developing innovative therapeutic platforms designed to address complex biological barriers to tissue repair.
Current focus
Regenerative wound care
Long-term potential
Broader dermatology therapeutics
Why Komava
From personal experience to scientific ambition.
Komava began with a personal experience.
When co-founder Mylène Talabardon’s father developed severe pressure ulcers, his treatment included honey-based wound dressings. Despite medical care, the wounds failed to heal, causing significant pain and ultimately leading to his death.
After more than 25 years working in biotechnology and biologics development, the experience raised a simple question: can we do better for patients with difficult-to-heal wounds?
That question became the starting point for Komava.
Chronic wounds remain a major healthcare challenge, with many patients experiencing prolonged healing, recurrent complications and a significant impact on quality of life.
Komava was founded with a clear objective: to develop therapeutic approaches that go beyond managing the wound environment and actively support the biological processes required for tissue repair.
Our ambition is to combine advances in biomaterials and regenerative medicine to develop practical therapies for patients with difficult-to-heal wounds.
Komava is building a modular therapeutic platform combining an advanced biomaterial with locally delivered therapeutic payloads.
Our current development programmes focus on chronic wounds, with neuroischemic diabetic foot ulcers as the lead indication.
The modular nature of the platform also provides the potential to expand beyond regenerative wound care and explore additional therapeutic applications in dermatology.
Experience across leading biotechnology and pharmaceutical companies.
Previous professional experience of Komava leadership team members.
Mylène Talabardon
Biogen/IDEC Pharmaceutical
Sanofi/Genzyme
Merck Serono
Ahmed Bouzidi
Vaxeal
SEDAC Therapeutics
European Biopharmaceutical Enterprises
Lytix Biopharma
Trinomab Biotech
ProductLife Group
Hervé Broly
Merck Serono
Company building and transactions
Founding and leading biotechnology companies, with experience in mergers, acquisitions, strategic partnerships and licensing agreements.
CMC and manufacturing
Process development and validation, technology transfer and scale-up to 20,000 L, clinical and commercial drug substance and drug product manufacturing, and manufacturing facility design and qualification.
Regulatory and submissions
Regulatory dossiers for IND, CTA, BLA and MAA submissions across Europe, the United States and China, including health authority interactions and regulatory inspections.
Development and launch
Preclinical and clinical development, CRO and CMO management, and multiple biologics successfully brought through regulatory approval and commercial launch.
Leadership team
Built by an experienced biotech team.
Komava is led by an executive team with deep experience in company management, product development, clinical trials, regulatory strategy, intellectual property, and go-to-market and post-market strategy.
Ahmed BouzidiPhD, MBA
Co-Founder, Director & Chief Executive Officer
30+ years in biotechnology
Ahmed’s senior executive experience in the biotechnology industry spans more than 30 years across Europe, China and the United States.
Founder and Chief Executive Officer of Vaxeal Holding and SEDAC Therapeutics, both in immunotherapy, with both successful exits
President of European Biopharmaceutical Enterprises, the biotech group within EFPIA
Senior executive roles at Lytix Biopharma, Trinomab Biotech and ProductLife Group
Extensive experience in private and public fundraising, mergers and acquisitions, and licensing
Ahmed’s senior executive experience in the biotechnology industry spans more than 30 years across Europe, China and the United States. Until recently he held senior executive positions in biotechnology SMEs and mid-cap companies including Lytix Biopharma, Trinomab Biotech and ProductLife Group. He also founded and served as Chief Executive Officer of Vaxeal Holding and SEDAC Therapeutics, two companies specialising in immunotherapy, with both successful exits. He was President of European Biopharmaceutical Enterprises, integrated into EFPIA, and a Board Member of Vaccines Europe. Ahmed has extensive experience in large private and public fundraising, mergers and acquisitions, and licensing. He holds a PhD in biology and an MBA from the University of New Hampshire in the United States.
Mylène TalabardonPhD
Co-Founder, President & Chief Scientific Officer
25+ years in biotechnology
Mylène brings 25 years of extensive experience in the biotechnology industry, with senior CMC leadership roles at Biogen, Sanofi and Merck Serono.
Senior chemistry, manufacturing and controls leadership at Biogen/IDEC Pharmaceutical, Sanofi/Genzyme and Merck Serono
Led a multi-disciplinary CMC team to commercial approval for a biosimilar
Contributed to multiple clinical and commercial drug substance and drug product manufacturing facilities
Process development and validation, technology transfer and scale-up, CRO and CMO management, regulatory requirements and product launches
Mylène brings 25 years of extensive experience in the biotechnology industry, having worked with renowned companies such as Biogen, Sanofi and Merck Serono. She has demonstrated exceptional leadership in chemistry, manufacturing and controls, contributing directly to multiple clinical and commercial drug substance and drug product manufacturing facilities in both technical and management roles. Prior to transitioning to consultancy, Mylène led a multi-disciplinary CMC team to successfully achieve commercial approval for a biosimilar. Her expertise encompasses process development and validation, innovative technologies, process technology transfer and scale-up, manufacturing operations and investigations, CRO and CMO management, continuous improvement, regulatory requirements and product launches.
Hervé BrolyPhD
Chief Technology Officer
40+ years in bioprocess development
Hervé is an internationally recognised bioprocess expert with more than 40 years of experience in the development, manufacture and validation of biotechnology processes.
Vice-President of Process Development at Merck Serono
Inventor or co-inventor of 21 patents
Author of 69 peer-reviewed scientific publications
CMC expertise across IND, CTA, BLA and MAA applications, leading to several approved submissions
Health authority interactions and site inspections
Hervé is an internationally recognised bioprocess expert with over 40 years of experience in the development, manufacture and validation of biotechnology processes. He is credited with 21 patents and has authored 69 scientific papers. Over his 35-year career at Merck Serono, he served as Vice-President of the Process Development Department. His expertise spans all CMC aspects of biotechnology products for IND, CTA, BLA and MAA applications, leading to the approval of several BLA and MAA submissions. He has extensive experience creating high-quality, compliant CMC regulatory documents and developing strategies for complex CMC challenges, and has played a crucial role in health authority interactions and inspections at company sites. Hervé is also a pioneer of skin cell technologies at CRTS Lille.
Building Komava
Combining scientific innovation with development experience.
Komava was created to combine innovative science with the development expertise required to transform promising therapeutic concepts into viable product candidates.
Our team brings together scientific, operational and entrepreneurial experience with a shared objective: to build differentiated therapies addressing significant unmet medical needs.
We welcome discussions with investors, scientific collaborators and development partners interested in advancing innovative therapies for chronic wounds.
